Krystal Biotech (NASDAQ:KRYS) Receives “Overweight” Rating from Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Krystal Biotech (NASDAQ:KRYS) in a research note released on Thursday,Benzinga reports. Cantor Fitzgerald currently has a $215.00 price objective on the stock.

A number of other analysts have also commented on the company. Citigroup boosted their price target on Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. HC Wainwright reissued a “buy” rating and issued a $221.00 target price on shares of Krystal Biotech in a research report on Wednesday. Finally, Chardan Capital upped their price target on Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research report on Thursday. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $210.00.

Krystal Biotech Trading Up 3.7 %

Krystal Biotech stock opened at $182.62 on Thursday. Krystal Biotech has a 1 year low of $107.50 and a 1 year high of $219.34. The company’s 50-day moving average is $157.18 and its two-hundred day moving average is $175.18. The company has a market cap of $5.25 billion, a PE ratio of 61.08 and a beta of 0.84.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, beating the consensus estimate of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The firm had revenue of $91.10 million during the quarter, compared to the consensus estimate of $91.35 million. During the same quarter in the prior year, the firm earned $0.30 earnings per share. The business’s quarterly revenue was up 116.4% on a year-over-year basis. Research analysts forecast that Krystal Biotech will post 6.14 EPS for the current year.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the sale, the insider now directly owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. This trade represents a 1.67 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 14.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Krystal Biotech

A number of large investors have recently bought and sold shares of KRYS. Summit Trail Advisors LLC bought a new position in shares of Krystal Biotech in the 3rd quarter worth $1,893,000. Entropy Technologies LP acquired a new position in Krystal Biotech during the fourth quarter worth $548,000. Swiss National Bank lifted its stake in shares of Krystal Biotech by 8.0% in the third quarter. Swiss National Bank now owns 39,100 shares of the company’s stock valued at $7,117,000 after buying an additional 2,900 shares in the last quarter. Janney Montgomery Scott LLC lifted its stake in shares of Krystal Biotech by 42.0% in the fourth quarter. Janney Montgomery Scott LLC now owns 52,592 shares of the company’s stock valued at $8,239,000 after buying an additional 15,545 shares in the last quarter. Finally, Citigroup Inc. grew its holdings in shares of Krystal Biotech by 65.4% during the third quarter. Citigroup Inc. now owns 35,084 shares of the company’s stock valued at $6,386,000 after buying an additional 13,874 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).